VEEV's UCB pharmacovigilance deal expands Safety Suite adoption, supporting automation, compliance and long-term growth opportunities.
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
VEEV's strong Q1, growing Vault CRM migrations and AI expansion support growth, though life sciences CRM market saturation poses risks.
Despite GE HealthCare's underperformance relative to the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Veeva Systems’ first quarter saw meaningful progress across its core business lines, with management attributing the results to broad-based customer demand and product execution in both R&D and commer
If you are looking at Veeva Systems and wondering whether the recent price is fair, expensive, or offers value, the next sections break down what the current valuation actually reflects. The stock las
VEEV's Falcon and Vault AI deepen workflow automation across life sciences, while management expects AI revenues to remain immaterial in fiscal 2027.
View interactive chart, options flow, and AI analysis for VEEV on Zorveq Finance.
Open VEEV Chart & Analysis →